<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| BONE-B (2 of 5) Internal request: | **Addition at call/meeting**  
Based on the data in the noted references and discussion, the panel consensus was to include vincristine to the regimen irinotecan ± temozolomide as an option for second-line relapsed/refractory or metastatic Ewing sarcoma. This is a category 2A recommendation.  
| | **Removal at call/meeting**  
Based on the data in the noted reference and discussion, the panel consensus was to remove the regimen vincristine + irinotecan in favor of irinotecan ± temozolomide ± vincristine for second-line relapsed/refractory or metastatic Ewing sarcoma.  
| BONE-B (2 of 5) External request: | Change not made  
Based on a review of data and discussion, the panel consensus did not support the inclusion of cabozantinib as a second-line systemic therapy option for relapsed/refractory or metastatic osteosarcoma and Ewing sarcoma due to insufficient available data.  
See Submission for references. | 20 | 0 | 0 | 7 |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>BONE-B (3 of 5) Internal request:</td>
<td>Comment to consider the inclusion of everolimus ± to sorafenib for second-line relapsed/refractory or metastatic osteosarcoma.</td>
<td>6</td>
<td>4</td>
<td>10</td>
</tr>
<tr>
<td>BONE-B (3 of 5) Internal request:</td>
<td>Comment to consider the inclusion of regorafenib for second-line relapsed/refractory or metastatic osteosarcoma.</td>
<td>20</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

**Addition at call/meeting**

Based on the data in the noted reference and discussion, the panel consensus was to include everolimus to sorafenib for second-line relapsed/refractory or metastatic disease for osteosarcoma. This is a category 2B recommendation.


**Addition at call/meeting**

Based on the data in the noted reference and discussion, the panel consensus was to include regorafenib for second-line relapsed/refractory or metastatic disease for osteosarcoma. This is a category 1 recommendation.

### BONE-B (3 of 5)

**Internal request:**

Consider removal of the regimen ifosfamide, cisplatin and epirubicin for first-line primary/neoadjuvant/adjuvant therapy or metastatic osteosarcoma.

**Removal at call/meeting**

The panel consensus was to remove the regimen ifosfamide, cisplatin and epirubicin for first-line primary/neoadjuvant/adjuvant therapy or metastatic disease for osteosarcoma due to limited clinical use.

|   | 20 | 0 | 0 | 7 |

**Internal request:**

Consider removal of Radium 233 (Ra 233) for second-line relapsed/refractory or metastatic osteosarcoma.

**Removal at call/meeting**

The panel consensus was to remove Radium 233 for second-line relapsed/refractory or metastatic disease for osteosarcoma due to limited clinical use.

|   | 20 | 0 | 0 | 7 |